These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 9918523)

  • 1. Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
    Tung CY; Granger CB; Sloan MA; Topol EJ; Knight JD; Weaver WD; Mahaffey KW; White H; Clapp-Channing N; Simoons ML; Gore JM; Califf RM; Mark DB
    Circulation; 1999 Jan; 99(3):370-6. PubMed ID: 9918523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.
    Barradell LB; Goa KL
    Pharmacoeconomics; 1995 Nov; 8(5):428-59. PubMed ID: 10172669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
    Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
    J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.
    Hudson MP; Granger CB; Topol EJ; Pieper KS; Armstrong PW; Barbash GI; Guerci AD; Vahanian A; Califf RM; Ohman EM
    Circulation; 2001 Sep; 104(11):1229-35. PubMed ID: 11551872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptokinase. A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction.
    Gillis JC; Goa KL
    Pharmacoeconomics; 1996 Sep; 10(3):281-310. PubMed ID: 10163575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators.
    Aylward PE; Wilcox RG; Horgan JH; White HD; Granger CB; Califf RM; Topol EJ
    Ann Intern Med; 1996 Dec; 125(11):891-900. PubMed ID: 8967669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
    Goel V; Naylor CD
    Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies.
    Barbash GI; Birnbaum Y; Bogaerts K; Hudson M; Lesaffre E; Fu Y; Goodman S; Houbracken K; Munsters K; Granger CB; Pieper K; Califf RM; Topol EJ; Van De Werf F
    Circulation; 2001 Feb; 103(7):954-60. PubMed ID: 11181469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries.
    Cox JL; Lee E; Langer A; Armstrong PW; Naylor CD
    CMAJ; 1997 Feb; 156(4):497-505. PubMed ID: 9054819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I.
    Kaul P; Armstrong PW; Chang WC; Naylor CD; Granger CB; Lee KL; Peterson ED; Califf RM; Topol EJ; Mark DB
    Circulation; 2004 Sep; 110(13):1754-60. PubMed ID: 15381645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W; Pierre K; Massel D
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient preferences for thrombolytic therapy in acute myocardial infarction.
    Stanek EJ; Cheng JW; Peeples PJ; Simko RJ; Spinler SA
    Med Decis Making; 1997; 17(4):464-71. PubMed ID: 9343805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French setting.
    Pelc A; Dardenne J; Frelon JH; Hanania G
    Pharmacoeconomics; 1997 Jun; 11(6):595-605. PubMed ID: 10173031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resource Use and Burden of Hospitalization, Outpatient, Physician, and Drug Costs in Short- and Long-term Care After Acute Myocardial Infarction.
    Tran DT; Welsh RC; Ohinmaa A; Thanh NX; Kaul P
    Can J Cardiol; 2018 Oct; 34(10):1298-1306. PubMed ID: 30170782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Lee KL; Califf RM; Simes J; Van de Werf F; Topol EJ
    Ann Intern Med; 1994 May; 120(10):876-81; discussion 882-5. PubMed ID: 8154647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial.
    Newby LK; Califf RM; Guerci A; Weaver WD; Col J; Horgan JH; Mark DB; Stebbins A; Van de Werf F; Gore JM; Topol EJ
    J Am Coll Cardiol; 1996 Mar; 27(3):625-32. PubMed ID: 8606274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.